CR20190147A - DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO - Google Patents

DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO

Info

Publication number: CR20190147A
Authority: CR; Costa Rica
Prior art keywords: mglur2; invención; del; trastornos; pharmaceutically acceptable
Prior art date: 2016-09-27

Application number

CR20190147A

Other languages

English (en)

Inventor

Iyassu K Sebhat

Ashok Arasappan

Duane Demong

Scott B Hoyt

Robert R Wilkening

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-09-27

Filing date

2017-09-25

Publication date

2019-05-17

2017-09-25 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2019-05-17 Publication of CR20190147A publication Critical patent/CR20190147A/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/24—Camphidines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

CR20190147A 2016-09-27 2017-09-25 DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO CR20190147A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662400150P	2016-09-27	2016-09-27
PCT/US2017/053155 WO2018063955A1 (en)	2016-09-27	2017-09-25	CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE

Publications (1)

Publication Number	Publication Date
CR20190147A true CR20190147A (es)	2019-05-17

Family

ID=60043302

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR20190147A CR20190147A (es)	2016-09-27	2017-09-25	DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO

Country Status (39)

Country	Link
US (4)	US10335399B2 (es)
EP (1)	EP3519416B1 (es)
JP (3)	JP6681517B2 (es)
KR (1)	KR102296043B1 (es)
CN (1)	CN109983022B (es)
AR (1)	AR109714A1 (es)
AU (2)	AU2017334870C1 (es)
CA (1)	CA3037537C (es)
CL (1)	CL2019000778A1 (es)
CO (1)	CO2019002673A2 (es)
CR (1)	CR20190147A (es)
CY (1)	CY1124346T1 (es)
DK (1)	DK3519416T3 (es)
DO (1)	DOP2019000076A (es)
EA (1)	EA038627B1 (es)
EC (1)	ECSP19020742A (es)
ES (1)	ES2868973T3 (es)
GE (4)	GEP20217266B (es)
HR (1)	HRP20210793T1 (es)
HU (1)	HUE054898T2 (es)
IL (1)	IL265366B (es)
JO (1)	JOP20190058B1 (es)
LT (1)	LT3519416T (es)
MA (1)	MA46342B1 (es)
MD (1)	MD3519416T2 (es)
MX (1)	MX392132B (es)
MY (1)	MY196807A (es)
NI (1)	NI201900025A (es)
PE (1)	PE20190609A1 (es)
PH (1)	PH12019500597B1 (es)
PL (1)	PL3519416T3 (es)
PT (1)	PT3519416T (es)
RS (1)	RS61890B1 (es)
SI (1)	SI3519416T1 (es)
TN (2)	TN2020000160A1 (es)
TW (1)	TWI764934B (es)
UA (1)	UA123687C2 (es)
WO (1)	WO2018063955A1 (es)
ZA (1)	ZA201901701B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CR20190147A (es) *	2016-09-27	2019-05-17	Merck Sharp & Dohme	DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
CN117964573B (zh)	2018-01-19	2026-04-14	赛特凯恩蒂克公司	作为心肌节抑制剂的二氢苯并呋喃和茚类似物
WO2020005888A1 (en)	2018-06-26	2020-01-02	Cytokinetics, Inc.	Cardiac sarcomere inhibitors
EP3814342B1 (en)	2018-06-26	2022-07-27	Cytokinetics, Inc.	Cardiac sarcomere inhibitors
BR112021017276A2 (pt) *	2019-03-01	2021-11-09	Kbp Biosciences Co Ltd	Método para preparar composto tricíclico e intermediário do mesmo
TW202302594A (zh)	2021-03-04	2023-01-16	美商胞質動力學公司	心臟肌節抑制劑
US20250340562A1 (en) *	2021-06-30	2025-11-06	The General Hospital Corporation	Chromane imaging ligands

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5552437A (en)	1994-10-27	1996-09-03	Merck Frosst Canada, Inc.	Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
US5576338A (en)	1995-02-15	1996-11-19	Merck Frosst Canada, Inc.	Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
WO2005014543A1 (ja)	2003-08-06	2005-02-17	Japan Tobacco Inc.	縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
CA2624294A1 (en)	2005-10-05	2007-04-12	Merck Frosst Canada Ltd.	Substituted quinolines as inhibitors of leukotriene biosynthesis
AR065093A1 (es)	2007-02-05	2009-05-13	Merck Frosst Canada Ltd	Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
PE20110368A1 (es)	2008-08-18	2011-06-13	Univ Yale	Moduladores de mif
NZ596078A (en) *	2009-05-12	2013-06-28	Janssen Pharmaceuticals Inc	1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
US8772301B2 (en)	2009-12-18	2014-07-08	Sunovion Pharmaceuticals, Inc.	Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
MX344308B (es) *	2011-11-03	2016-12-13	Merck Sharp & Dohme	Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
WO2016029454A1 (en)	2014-08-29	2016-03-03	Merck Sharp & Dohme Corp.	TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
US9382208B1 (en)	2015-01-26	2016-07-05	Vanderbilt University	Negative allosteric modulators of metabotropic glutamate receptor 2
US10538491B2 (en)	2015-03-16	2020-01-21	Vanderbilt University	4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
JP6471614B2 (ja)	2015-05-29	2019-02-20	株式会社リコー	通信端末、通信システム、通信制御方法、及びプログラム
JP2018154554A (ja)	2015-07-29	2018-10-04	大日本住友製薬株式会社	新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途
CR20190147A (es) *	2016-09-27	2019-05-17	Merck Sharp & Dohme	DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO

2017
- 2017-09-25 CR CR20190147A patent/CR20190147A/es unknown
- 2017-09-25 DK DK17781253.4T patent/DK3519416T3/da active
- 2017-09-25 SI SI201730727T patent/SI3519416T1/sl unknown
- 2017-09-25 PH PH1/2019/500597A patent/PH12019500597B1/en unknown
- 2017-09-25 TW TW106132824A patent/TWI764934B/zh not_active IP Right Cessation
- 2017-09-25 MA MA46342A patent/MA46342B1/fr unknown
- 2017-09-25 JO JOP/2019/0058A patent/JOP20190058B1/ar active
- 2017-09-25 RS RS20210649A patent/RS61890B1/sr unknown
- 2017-09-25 GE GEAP201715056A patent/GEP20217266B/en unknown
- 2017-09-25 UA UAA201904545A patent/UA123687C2/uk unknown
- 2017-09-25 LT LTEP17781253.4T patent/LT3519416T/lt unknown
- 2017-09-25 AU AU2017334870A patent/AU2017334870C1/en not_active Ceased
- 2017-09-25 PL PL17781253T patent/PL3519416T3/pl unknown
- 2017-09-25 MD MDE20190867T patent/MD3519416T2/ro unknown
- 2017-09-25 EP EP17781253.4A patent/EP3519416B1/en active Active
- 2017-09-25 GE GEAP202115310A patent/GEAP202115310A/en unknown
- 2017-09-25 TN TNP/2020/000160A patent/TN2020000160A1/en unknown
- 2017-09-25 PE PE2019000706A patent/PE20190609A1/es unknown
- 2017-09-25 CA CA3037537A patent/CA3037537C/en active Active
- 2017-09-25 EA EA201990818A patent/EA038627B1/ru unknown
- 2017-09-25 HU HUE17781253A patent/HUE054898T2/hu unknown
- 2017-09-25 GE GEAP201715310A patent/GEP20217279B/en unknown
- 2017-09-25 GE GEAP202115056A patent/GEAP202115056A/en unknown
- 2017-09-25 US US15/713,769 patent/US10335399B2/en active Active
- 2017-09-25 WO PCT/US2017/053155 patent/WO2018063955A1/en not_active Ceased
- 2017-09-25 CN CN201780071759.0A patent/CN109983022B/zh not_active Expired - Fee Related
- 2017-09-25 KR KR1020197011789A patent/KR102296043B1/ko not_active Expired - Fee Related
- 2017-09-25 AR ARP170102642A patent/AR109714A1/es active IP Right Grant
- 2017-09-25 JP JP2019516203A patent/JP6681517B2/ja not_active Expired - Fee Related
- 2017-09-25 ES ES17781253T patent/ES2868973T3/es active Active
- 2017-09-25 TN TNP/2020/000161A patent/TN2020000161A1/en unknown
- 2017-09-25 MX MX2019003492A patent/MX392132B/es unknown
- 2017-09-25 MY MYPI2019001659A patent/MY196807A/en unknown
- 2017-09-25 HR HRP20210793TT patent/HRP20210793T1/hr unknown
- 2017-09-25 PT PT177812534T patent/PT3519416T/pt unknown
2019
- 2019-03-13 IL IL265366A patent/IL265366B/en unknown
- 2019-03-19 ZA ZA2019/01701A patent/ZA201901701B/en unknown
- 2019-03-20 NI NI201900025A patent/NI201900025A/es unknown
- 2019-03-22 CO CONC2019/0002673A patent/CO2019002673A2/es unknown
- 2019-03-25 CL CL2019000778A patent/CL2019000778A1/es unknown
- 2019-03-26 DO DO2019000076A patent/DOP2019000076A/es unknown
- 2019-03-28 EC ECSENADI201920742A patent/ECSP19020742A/es unknown
- 2019-04-23 US US16/392,131 patent/US10806724B2/en active Active
- 2019-09-30 JP JP2019178232A patent/JP6945605B2/ja not_active Expired - Fee Related
2020
- 2020-03-23 JP JP2020051049A patent/JP6992109B2/ja not_active Expired - Fee Related
- 2020-09-25 US US17/032,626 patent/US20210015800A1/en not_active Abandoned
- 2020-11-16 AU AU2020270468A patent/AU2020270468B2/en not_active Ceased
2021
- 2021-05-31 CY CY20211100468T patent/CY1124346T1/el unknown
2022
- 2022-03-15 US US17/695,262 patent/US20220218676A1/en active Pending

Also Published As

Publication number	Publication date
AU2017334870C1 (en)	2020-12-17
MD3519416T2 (ro)	2021-09-30
EP3519416A1 (en)	2019-08-07
JP2020011989A (ja)	2020-01-23
IL265366A (en)	2019-05-30
SI3519416T1 (sl)	2021-08-31
JOP20190058B1 (ar)	2023-09-17
GEAP202115056A (en)	2021-01-25
KR102296043B1 (ko)	2021-08-30
TW201815794A (zh)	2018-05-01
NI201900025A (es)	2019-05-27
HRP20210793T1 (hr)	2021-09-03
ECSP19020742A (es)	2019-04-30
CY1124346T1 (el)	2022-07-22
GEP20217279B (en)	2021-08-10
PH12019500597A1 (en)	2019-07-24
MX392132B (es)	2025-03-12
CO2019002673A2 (es)	2019-03-29
PL3519416T3 (pl)	2021-09-06
US10335399B2 (en)	2019-07-02
LT3519416T (lt)	2021-06-10
JP2020111596A (ja)	2020-07-27
TN2020000160A1 (en)	2022-04-04
ZA201901701B (en)	2023-03-29
JP6992109B2 (ja)	2022-02-15
CA3037537C (en)	2021-06-15
PT3519416T (pt)	2021-05-13
AU2017334870A1 (en)	2019-03-28
IL265366B (en)	2021-12-01
DOP2019000076A (es)	2019-07-15
AU2020270468B2 (en)	2022-02-17
AR109714A1 (es)	2019-01-16
EA201990818A1 (ru)	2019-08-30
WO2018063955A1 (en)	2018-04-05
UA123687C2 (uk)	2021-05-12
AU2020270468A1 (en)	2020-12-10
PH12019500597B1 (en)	2023-05-10
EA038627B1 (ru)	2021-09-24
AU2017334870B2 (en)	2020-08-20
TN2020000161A1 (en)	2022-04-04
JP6681517B2 (ja)	2020-04-15
US10806724B2 (en)	2020-10-20
DK3519416T3 (da)	2021-05-25
ES2868973T3 (es)	2021-10-22
TWI764934B (zh)	2022-05-21
CL2019000778A1 (es)	2019-05-31
PE20190609A1 (es)	2019-04-23
BR112019005869A2 (pt)	2019-06-11
JP2019529468A (ja)	2019-10-17
CN109983022B (zh)	2022-06-07
MA46342A (fr)	2019-08-07
HUE054898T2 (hu)	2021-10-28
CN109983022A (zh)	2019-07-05
GEP20217266B (en)	2021-06-25
BR112019005869A8 (pt)	2023-05-02
RS61890B1 (sr)	2021-06-30
CA3037537A1 (en)	2018-04-05
US20210015800A1 (en)	2021-01-21
EP3519416B1 (en)	2021-03-31
KR20190056418A (ko)	2019-05-24
MA46342B1 (fr)	2021-05-31
MX2019003492A (es)	2019-09-19
US20180085358A1 (en)	2018-03-29
JOP20190058A1 (ar)	2019-03-24
GEAP202115310A (en)	2021-04-12
US20220218676A1 (en)	2022-07-14
MY196807A (en)	2023-05-03
US20190247374A1 (en)	2019-08-15
JP6945605B2 (ja)	2021-10-06

Publication	Publication Date	Title
ECSP19020742A (es)	2019-04-30	DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
MX344308B (es)	2016-12-13	Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
NI201100100A (es)	2011-09-12	Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
CO2022010460A2 (es)	2022-08-09	Compuestos tricíclicos sustituidos
CO2022000749A2 (es)	2022-02-07	Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
MX2022006475A (es)	2022-09-07	Compuestos triciclicos sustituidos.
BR112015029512A8 (pt)	2019-12-17	derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112012021086A2 (pt)	2016-05-17	composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
MX2019014982A (es)	2020-02-24	Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos.
BR112013009365A2 (pt)	2016-07-26	uso de um composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável solvato ou composição do mesmo, composto da formula (i), composição farmaceutica, metodo para o tratamento de uma condição ou desordem em que bloqueadores de canal ttx-s estao envolvidos em um animal, incluindo um humano e processo para preparar uma composiçao farmaceutica.
AR127470A1 (es)	2024-01-31	Inhibidores de lrrk2
CL2023002635A1 (es)	2024-03-15	Derivados de 3h,4h,5h,6h,7h-pirimido[4,5-b][1,4]oxazin-4,6-diona como inhibidores de trpa1
CO2019003894A2 (es)	2019-04-30	Derivados de naftiridinona y su uso en el tratamiento de la arritmia
AR120174A1 (es)	2022-02-02	Inhibidores del factor d del complemento para administración oral
BR112019024804A2 (pt)	2020-06-09	compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas
MX2021009584A (es)	2021-09-23	Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih).
MX2022006266A (es)	2022-11-10	Derivados macrociclicos de panteteina y usos de los mismos.
EA201270825A1 (ru)	2013-05-30	Применение производного эстрогена для производства фармацевтических композиций, пригодных для лечения и/или предотвращения психиатрических заболеваний, и для лечения и предотвращения указанных заболеваний
EA201992577A1 (ru)	2020-03-30	5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний